"There has been a lot of debate regarding the role of IP therapy in microscopic and macroscopic residual disease, and we saw an advantage in this cohort in both specific groups," commented Dr. Tewari.
Overall, half of patients given IP chemotherapy completed all six cycles of that chemotherapy. The risk of death fell with each additional cycle of IP chemotherapy (hazard ratio, 0.88, P less than .001).
Dr. Tewari disclosed no conflicts of interest related to the research.